We have performed extensive multiconfiguration Dirac-Hartree-Fock calculations and second-order many-body perturbation calculations for F-like ions with Z=24-30. Energy levels and transition rates for electric dipole (E1), electric-quadrupole (E2), electric-octupole (E3), magnetic dipole (M1), and magnetic-quadrupole (M2) transitions, as well as radiative lifetimes, are provided for the lowest 200 levels belonging to the s s p configurations of each ion. The results from the two sets of calculations are in excellent agreement. Extensive comparisons are also made with other theoretical results and observed data from the CHIANTI and NIST databases. The present energies and wavelengths are believed to be accurate enough to aid line identifications involving the n=3 and n=4 configurations, for which observations are largely missing. The calculated wavelengths and transition data will be useful in the modeling and diagnostics of astrophysical and fusion plasmas.

To evaluate the efficacy and safety of CyberKnife Stereotactic Body Radiation Therapy (SBRT) in the treatment of adrenal gland metastases (AGM), we designed a large-scale multicenter retrospective study to report the safety and efficacy of SBRT for inoperable AGM. In this study, 75 (61 males, 14 females) patients with 84 AGM and Karnofsky performance score ≥70 were treated by SBRT from October 2006 to January 2017. Of these, the purpose of treatment were controlling all known metastatic sites for 21 patients while 54 for palliation of bulky adrenal metastases. The efficacy and safety of SBRT were evaluated during follow-up. Potential factors predictive of local control (LC) and overall survival (OS) were identified by univariate and multivariate analysis. Median follow-up time was 12.7 months (range 1.8-96.4). The complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) rates were 23.8%, 23.8%, 31.0% and 21.4%, respectively. The 0.5, 1, and 2-year LC rates were 93.6%, 83.8%, and 62.1%, respectively; OS rates on the same follow-up intervals were 93.7%, 62.5%, and 49.6%, respectively, and the corresponding PFS rates were 48.5%, 33.9%, and 16.0%, respectively. The treatment was well tolerated with 2 patients reporting grade-3 diarrhea and fatigue, respectively. Multivariate analysis showed that simultaneous treatment of SBRT for other metastatic lesions, the number of AGM, initiation of systemic therapy, and the maximum diameter of AGM were predictive of LC rates. Moreover, patients with AGM < 5 cm had a superior OS compared with those with AGM ≥ 5 cm (28.0 months vs. 17.6 months, P = 0.032). SBRT is an effective therapeutic option for treatment of AGM with high LC rates with minimal toxicity. The adrenal gland is one of the commonest metastatic sites in primary tumors of lungs, liver, renal, colorectal, and lymphoma 1. Patients with adrenal gland metastases (AGM) have back or abdominal pain occasionally along with the growth of tumor 2. Rarely, patients with bilateral adrenal metastases may occur adrenal insufficiency which compromises quality of life (QOL) and results in worse outcomes 2. Although salvage chemotherapy and surgery are commonly used to treat AGM, limitations are inevitable. It is mandatory that pathological examinations of the primary tumor should be performed to guide decision making of chemotherapy regimens. Nevertheless, second-line chemotherapy may be less effective or may contribute to severe toxicities when the disease progresses after first-line chemotherapy has failed. Moreover, surgical resection may bring about adrenal insufficiency or other morbidities albeit it is regarded with curative intent 3. Hence, radiotherapy may be an alternative due to its potential efficacy and less risk of adverse effects compared to chemotherapy and surgery.

No abstract